Resources

This fact sheet provides an overview of PATH's Center for Vaccine Innovation and Access (CVIA), which works in partnership to develop and deliver lifesaving vaccines to women, children, and communities around the globe. It highlights the critical role that CVIA has had in some of immunization’s greatest successes, saving countless lives and improving health for hundreds of millions around the world. It also provides information about CVIA's broad range of expertise and capabilities.

Neonatal mortality is a critical challenge in underserved areas like Dharni, Maharashtra, where limited access to healthcare and tough terrain hinder timely medical intervention. To address this, PATH, in collaboration with AIIMS Nagpur, introduced a tele-SNCU hub-and-spoke model, leveraging telemedicine to provide real-time consultations and remote monitoring for newborns. This project brief highlights the implementation of this tele-SNCU model, which has significantly reduced neonatal deaths and referrals, enhancing care quality and contributing to progress toward SDG targets.

This is a simple, Excel-based tool for assessing and comparing costs of pneumococcal conjugate vaccine (PCV) vaccination programs with each PCV product available in the global market. It aims to help national-level policymakers specifically in countries eligible for support from Gavi, the Vaccine Alliance, compare products and estimate vaccination program costs for different PCVs, exploring up to four different vaccine options at a time.The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery). Cost estimates are provided separately for the country perspective and the combined country and Gavi perspective.It is important to note that cost is only one consideration when selecting a PCV product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages below. Please be sure to check out this seven-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. If you have additional questions or need support, contact PATH’s Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.

Artemisinin-based combination therapy (ACT) is the primary malaria treatment in most malaria-endemic countries. To better understand the current ACT market and supply chain, PATH developed a market landscape with useful market information for stakeholders that purchase, procure, or use ACTs.The content of this landscape focuses on the current state of the ACT market—including supply, demand, market shares and prices, and active pharmaceutical ingredient and artemisinin suppliers.PATH hopes this landscape will be a valuable resource for partners, and we welcome any feedback or suggestions on the document.

A robust malaria surveillance system is the backbone of malaria control and elimination. Data visualization, analysis and use are critical to better understanding the data produced by malaria surveillance systems, assessing and communicating their implications for national malaria programs, and leveraging data and learnings to inform decision-making on implementation of malaria interventions.PATH's Malaria Control and Elimination Partnership in Africa (MACEPA) works with national malaria programs and district health teams to generate high-quality, actionable data products through functional surveillance systems, and increase data use for timely decision making. In collaboration with the Ministry of Health (MoH), PATH MACEPA in partnership with Bluesquare developed and facilitated the development and rollout of a national malaria intelligence platform to guide and inform malaria decision making in the Democratic Republic of the Congo (DRC).An overview of the process, challenges faced, lessons learned, and recommendations are documented and described in this technical brief.